Colon Cancer Data Key as Pfizer Buys Array.
Pfizer announced plans to acquire Array BioPharma, maker of a BRAF-MEK inhibitor combination that is currently approved for melanoma and could become a first-in-class treatment for colorectal cancer. The $11.4 billion deal also lands Pfizer a small pipeline of other targeted cancer medicines in development and a portfolio of out-licensed medicines with the potential to generate substantial royalties.